GlassScriptPhysician profile
Maradixy Suarez
NPI 1043929961
$713.45
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $690 · 2024: $23.83.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $674 · Education: $39.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $673.62 |
| Education | $39.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $157.67 | 2023 | Lupkynis |
| Abbvie INC. | $102.23 | 2023 | |
| Novartis Pharmaceuticals Corporation | $77.35 | 2023-2024 | |
| Lilly USA, LLC | $63.33 | 2023 | Taltz |
| Ucb, INC. | $60.82 | 2023 | Cimzia |
| Amgen INC. | $39.52 | 2023 | Enbrel, Tavneos |
| Alexion Pharmaceuticals, INC. | $34.98 | 2023 | Strensiq |
| Astrazeneca Pharmaceuticals LP | $33.26 | 2023 | Saphnelo |
| Celltrion USA INC. | $31.60 | 2023 | Yuflyma |
| Kyowa Kirin, INC. | $28.86 | 2023 | Crysvita |
| Radius Health, INC. | $25.14 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.47 | 2023 | |
| Kiniksa Pharmaceuticals, LTD. | $20.79 | 2023 | Arcalyst |
| Sandoz INC. | $15.43 | 2023 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maradixy Suarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.